Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0000905148-25-001900

President and CEO gave up 19,904 shares (to pay taxes)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Blume-Jensen Peter President and CEO 2025-05-21 Shares withheld for taxes −19,904 $1.15 $22,890 2,206,111 D: show line 1 in the form
Loading xslF345X05/form4.xml…